Pancreatic Cancer Research

ResearcherCleveland ClinicActive in the last 2 years

Jeffrey E. Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6010-5590; OpenAlex author ID A5022491856, A5113836523. Sources: OpenAlex.

Their work

Papers
91 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
156
Papers, trials and grants by year

2011: 3 papers · 2012: 15 papers · 2013: 4 papers · 2014: 6 papers · 2015: 4 papers · 2016: 4 papers · 2017: 6 papers · 2018: 6 papers · 2019: 14 papers · 2020: 4 papers · 2021: 9 papers · 2022: 5 papers · 2023: 6 papers · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 50 of 91

  1. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  2. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  3. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  4. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  5. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  6. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  7. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05534-3↗
  8. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  9. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  10. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  11. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  12. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Co-author DOI 10.1002/jso.26989↗
  13. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  14. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Co-author DOI 10.1016/j.suronc.2021.101673↗
  15. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  16. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  17. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Co-author DOI 10.1002/jso.26394↗
  18. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Co-author DOI 10.1002/jso.26650↗
  19. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  20. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  21. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Co-author DOI 10.1016/j.pan.2021.08.006↗
  22. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  23. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09013-4↗
  24. Factors Influencing Exercise Following Pancreatic Tumor Resection. Co-author DOI 10.1245/s10434-020-09062-9↗
  25. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09518-y↗
  26. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  27. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Co-author DOI 10.1007/s11605-019-04126-y↗
  28. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  29. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  30. Physical activity and exercise during preoperative pancreatic cancer treatment. Co-author DOI 10.1007/s00520-018-4493-6↗
  31. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2018.10.009↗
  32. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimi… Co-author DOI 10.1016/j.hpb.2018.10.018↗
  33. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. Co-author DOI 10.1016/j.hpb.2019.01.011↗
  34. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2019.04.090↗
  35. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Co-author DOI 10.1097/mpa.0000000000001231↗
  36. Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2α in Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001248↗
  37. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… Co-author DOI 10.1097/mpa.0000000000001345↗
  38. Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001432↗
  39. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. Co-author DOI 10.1123/jpah.2019-0027↗
  40. Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. Co-author DOI 10.1177/1534735419894061↗
  41. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  42. Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-018-07093-x↗
  43. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  44. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  45. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. Co-author DOI 10.1002/jso.25067↗
  46. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-017-3618-4↗
  47. Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard? Last author DOI 10.1097/sla.0000000000002783↗
  48. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.aat3487↗
  49. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  50. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗

Closest collaborators

The 25 strongest of 156 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 89 shared papers, 2011–2026 · strength 7.49
  2. Ching-Wei David Tzeng · 48 shared papers, 2012–2026 · strength 5.60
  3. Michael P. Kim · 43 shared papers, 2016–2026 · strength 5.43
  4. Laura R. Prakash · 35 shared papers, 2015–2026 · strength 4.21
  5. Naruhiko Ikoma · 25 shared papers, 2020–2026 · strength 3.91
  6. Robert A. Wolff · 49 shared papers, 2011–2025 · strength 3.25
  7. Huamin Wang · 42 shared papers, 2012–2023 · strength 2.55
  8. Jason B. Fleming · 52 shared papers, 2011–2022 · strength 2.35
  9. Gauri Rajani Varadhachary · 43 shared papers, 2011–2022 · strength 2.26
  10. Eugene Jon Koay · 23 shared papers, 2014–2025 · strength 2.12
  11. Anirban Maitra · 24 shared papers, 2014–2023 · strength 1.84
  12. Jean‐Nicolas Vauthey · 26 shared papers, 2012–2023 · strength 1.53
  13. Rebecca Anne Snyder · 7 shared papers, 2016–2026 · strength 1.44
  14. David R. Fogelman · 20 shared papers, 2012–2021 · strength 1.32
  15. Milind M. Javle · 18 shared papers, 2011–2023 · strength 1.20
  16. Timothy Eric Newhook · 7 shared papers, 2021–2026 · strength 1.14
  17. Shubham Pant · 9 shared papers, 2020–2025 · strength 1.10
  18. Hua Wang · 15 shared papers, 2012–2023 · strength 0.93
  19. Michael James Overman · 11 shared papers, 2016–2023 · strength 0.93
  20. Christopher H. Crane · 22 shared papers, 2011–2022 · strength 0.88
  21. Peter W. T. Pisters · 25 shared papers, 2011–2017 · strength 0.80
  22. Nathan H. Parker · 10 shared papers, 2014–2023 · strength 0.76
  23. Priya Bhosale · 12 shared papers, 2012–2022 · strength 0.73
  24. An Ngo‐Huang · 8 shared papers, 2015–2023 · strength 0.67
  25. Deyali Chatterjee · 12 shared papers, 2012–2023 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.